Thursday, March 16, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

DHS Awards Antibody Development Contract for Biothreat Agents

by Global Biodefense Staff
May 7, 2014
Antibody Research Immunoassays

Credit: Shutterstock

The Department of Homeland Security (DHS) recently announced intentions to award a sole source contract to Silver Lake Research Corporation (SLRC) for continued development of threat agent specific monoclonal antibodies for which current gold standards methods are not able to generate a highly specific product to support the development of rapid detection assays.

The effort is managed by the DHS Directorate of Science and Technology (S&T), Chemical and Biological Defense Division (CBD).

“SLRC has produced a group of highly specific monoclonal antibodies for use in DHS and FEDGOV assays. The technology and methods used are company proprietary and unavailable from any other source,” states the announcement. “Since the Contractor’s access to their innovative and unique intellectual property are critically necessary to perform the work; the only viable alternative for the Government would be to proceed as recommended with a sole source option and is critical to S&T/CBD that the work be completed.”

S&T CBD requires that SLRC continue and complete the work for the research, development and generation of hyper-specific monoclonal antibodies specific for bacterial and viral biothreat agents.

SLRC is based in Monravia, Calif. The company develops and manufactures innovative very high affinity antibody-based products using a proprietary immunization technology, called the Enhanced Affinity Platform, or EAP™ System.

Source: FBO.gov

Tags: Chemical Detection

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy